Skip to main
SPTX

SPTX Stock Forecast & Price Target

SPTX Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Seaport Therapeutics is a promising biopharmaceutical company with a strong management team and a diverse pipeline of drugs, including their lead assets GlyphAllo and GlyphAgo. Their innovative technology platform, Glyph, has the potential to revolutionize drug delivery and address the significant market demand for new treatments for depression and anxiety. Along with their success with CAPLYTA®, their strong intellectual property portfolio and exclusivity in Europe and Japan make Seaport a strong contender in the field of neuropsychiatry. However, potential investors should be aware of the risks associated with the clinical, regulatory, and commercial aspects of drug development.

Bears say

Seaport Therapeutics is a clinical-stage therapeutics company with a focus on developing new medicines for patients with depression, anxiety, and other neuropsychiatric disorders. While their pipeline products are based on a clinically validated technology, their lead programs in neuropsychiatry carry significant clinical risk. Additionally, previous failures in clinical trials for similar drugs in the same category add to the negative outlook for Seaport Therapeutics. Furthermore, there are concerns regarding the conduct of the company's ph3 trials for their lead program in MDD, potentially impacting the success of their other programs.

SPTX has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Seaport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Seaport Therapeutics Inc (SPTX) Forecast

Analysts have given SPTX a Strong Buy based on their latest research and market trends.

According to 6 analysts, SPTX has a Strong Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Seaport Therapeutics Inc (SPTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.